AorTech blames Ultracor for disappointing results:
This article was originally published in Clinica
Executive Summary
AorTech International, a UK company which produces the Ultracor mechanical heart valve, says that a downturn in its annual sales, from last year's £2.2 million ($3.6 million) to this year's £1.8 million was due primarily to disappointing sales of the valves. However, losses also diminished. The company is predicting that the results of a major study in Germany on the valve's performance should have a "significant positive impact on sales during ensuing years". AorTech raised $3 million in May through a share issue to new and existing shareholders (see Clinica No 809, p 11).
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.